Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the de...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/8/11/511 |
| _version_ | 1797547582985076736 |
|---|---|
| author | Joachim Brumberg Melanie Beckl Alexander Dierks Andreas Schirbel Markus Krebs Andreas Buck Hubert Kübler Constantin Lapa Anna Katharina Seitz |
| author_facet | Joachim Brumberg Melanie Beckl Alexander Dierks Andreas Schirbel Markus Krebs Andreas Buck Hubert Kübler Constantin Lapa Anna Katharina Seitz |
| author_sort | Joachim Brumberg |
| collection | DOAJ |
| description | Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of <sup>68</sup>Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and <sup>68</sup>Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All <sup>68</sup>Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, <i>p</i> = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (<i>p</i> < 0.01) and PSMA-derived tumor volume (<i>p</i> < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended. |
| first_indexed | 2024-03-10T14:47:06Z |
| format | Article |
| id | doaj.art-bf50cf32673a4fef8f4f4b335ac271d4 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T14:47:06Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-bf50cf32673a4fef8f4f4b335ac271d42023-11-20T21:21:00ZengMDPI AGBiomedicines2227-90592020-11-0181151110.3390/biomedicines8110511Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation TherapyJoachim Brumberg0Melanie Beckl1Alexander Dierks2Andreas Schirbel3Markus Krebs4Andreas Buck5Hubert Kübler6Constantin Lapa7Anna Katharina Seitz8Department of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Urology, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Urology, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyDepartment of Urology, University Hospital Würzburg and Julius-Maximilian University Würzburg, 97080 Würzburg, GermanyProstate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of <sup>68</sup>Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and <sup>68</sup>Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All <sup>68</sup>Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, <i>p</i> = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (<i>p</i> < 0.01) and PSMA-derived tumor volume (<i>p</i> < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.https://www.mdpi.com/2227-9059/8/11/511<sup>68</sup>Ga-PSMA ligand PET/CTandrogen deprivation therapydetection raterecurrent prostate cancer |
| spellingShingle | Joachim Brumberg Melanie Beckl Alexander Dierks Andreas Schirbel Markus Krebs Andreas Buck Hubert Kübler Constantin Lapa Anna Katharina Seitz Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy Biomedicines <sup>68</sup>Ga-PSMA ligand PET/CT androgen deprivation therapy detection rate recurrent prostate cancer |
| title | Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy |
| title_full | Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy |
| title_fullStr | Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy |
| title_full_unstemmed | Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy |
| title_short | Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy |
| title_sort | detection rate of sup 68 sup ga psma ligand pet ct in patients with recurrent prostate cancer and androgen deprivation therapy |
| topic | <sup>68</sup>Ga-PSMA ligand PET/CT androgen deprivation therapy detection rate recurrent prostate cancer |
| url | https://www.mdpi.com/2227-9059/8/11/511 |
| work_keys_str_mv | AT joachimbrumberg detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT melaniebeckl detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT alexanderdierks detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT andreasschirbel detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT markuskrebs detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT andreasbuck detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT hubertkubler detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT constantinlapa detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy AT annakatharinaseitz detectionrateofsup68supgapsmaligandpetctinpatientswithrecurrentprostatecancerandandrogendeprivationtherapy |